不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞淋巴瘤的新二线治疗
英文原题：New Second-Line Treatment for B-Cell Lymphoma.
查看英文原题
New Second-Line Treatment for B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
阿基仑赛（Yescarta）已获批作为大B细胞淋巴瘤患者的二线药物，用于对一线化学免疫治疗耐药或在12个月内复发的患者。确认患者身份并与药物匹配至关重要，因为这是自体输注。护士应给患者进行预用药，以尽量减少超敏反应的风险。
展开英文摘要原文
Axicabtagene ciloleucel (Yescarta) has been approved for use as a second-line drug in patients with large B-cell lymphoma who are resistant to, or who relapse within 12 months of, first-line chemoimmunotherapy.Confirming the patient's identity and matching it to the drug are critical as this is an autologous infusion. Nurses should premedicate patients to minimize the risk of hypersensitivity reactions.
论文信息
- 作者
- Aschenbrenner DS
- 单位
- Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .United States
- 期刊
- The American journal of nursing2022 Aug 1
- 原文标识
- PubMed 35862599 · DOI 10.1097/01.NAJ.0000854972.82263.fc